What Happened in the Stock Market Today
Mylan plans to merge with a spinoff from Pfizer, and Merck had more good news about its blockbuster cancer drug.
Mylan
MYL
MYL
$18.58
-$0.32
-1.7%
BATS BZX Real Time Price as of October 14, 2019, 12:35 p.m. EDT
View Interactive MYL Charts
The Company develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients.
News & Analysis: Mylan
The Fool has written over 200 articles on Mylan.
Mylan's Mixed 2nd-Quarter Results Overshadowed by News of Its Upjohn Merger
The drugmaker's revenue improved in the second quarter with new product launches, but higher spending weighed on its earnings.
Why Mylan Stock Is Jumping Today
A proposed combination with Pfizer's Upjohn unit is exciting Mylan shareholders.
Stock Market News: Pfizer and Mylan Make a Deal; Chipotle Looks Tasty
Stocks were mixed on Wall Street Monday morning.
Pfizer Closes in on a Major Spinoff
The pharmaceutical giant will reportedly combine its legacy products business with generic drug major Mylan.
Here's Why Generic-Drug Manufacturers Lost As Much As 43.2% in May
The industry drew the ire of 44 state attorneys general alleging widespread conspiracy to inflate drug prices.
Here's Why Generic-Drug Manufacturers Were Down Monday
Forty-four states have brought a lawsuit against the industry.
Mylan N.V. (MYL) Q1 2019 Earnings Call Transcript
MYL earnings call for the period ending March 31, 2019.
Mylan's Struggles Continue in the First Quarter
The drugmaker's challenges in the U.S. generics market and problems at a manufacturing facility weighed on its first-quarter revenue and earnings.
Why Mylan Stock Is Sinking Today
The drugmaker's Q1 update is weighing on its share price.
